Abeona Therapeutics vs Keros Therapeutics
ABEO and KROS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABEO and KROS compare
Keros Therapeutics is the larger company, worth 1.5 times as much as Abeona Therapeutics ($204M against $138M).
Keros Therapeutics keeps more of each dollar of sales as profit, with a net margin of −153% compared with −160% at Abeona Therapeutics.
Keros Therapeutics scores higher on the StockData Score (9 against 8 for Abeona Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABEO | KROS |
|---|---|---|
| Size and price | ||
| Market cap | $138M | $204M |
| Share price | $2.42 | $10.30 |
| Change, 1 year | −51.0% | −41.0% |
| Change, 5 years | −86.9% | −82.8% |
| Beta (5Y) | 1.30 | 1.11 |
| Employees | 226 | 78 |
| StockData Score | ||
| Total score | 8 | 9 (better) |
| Valuation score | 3 | 3 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.5× (better) | 5.1× |
| P/B | 1.1× | 0.7× (better) |
| FCF yield | −47.9% | −23.6% (better) |
| Fair value | $3.99 | $24.09 |
| Margin of safety | 39.4% | 57.3% (better) |
| Growth | ||
| Revenue growth (TTM) | – | −83.4% |
| Revenue growth, 5Y average | −10.3% | – |
| Net income growth (TTM) | −176% (better) | −196% |
| EPS growth (TTM) | – | −282% |
| Profitability | ||
| Gross margin | 65.1% | – |
| Operating margin | −186% | −181% (better) |
| Net margin | −160% | −153% (better) |
| FCF margin | −170% | −119% (better) |
| Return on equity | −42.1% | −12.6% (better) |
| Return on invested capital | – | −389% |
| Financial health | ||
| Debt / equity | 0.09 (better) | 0.00 |
| Interest coverage | −24.5× | – |
| Current ratio | 5.69 | 18.14 (better) |
| Altman Z-score | −4.84 | 2.37 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 77.9% | 101% |
| Held by insiders | 12.3% | 53.3% |
| Insider net buying, 12 months | −$3.5M | −$447K (better) |
| Short interest, % of float | 33.6% | 11.7% |
Go deeper
- ABEO stock overview
- ABEO income statement
- ABEO valuation and score
- KROS stock overview
- KROS income statement
- KROS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.